BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9280223)

  • 1. Combined modality therapy of non-small cell lung cancer.
    Ruckdeschel JC
    Semin Oncol; 1997 Aug; 24(4):429-39. PubMed ID: 9280223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality therapy for non-small-cell lung cancer.
    Lilenbaum RC; Green MR
    Oncology (Williston Park); 1994 May; 8(5):25-31; discussion 32, 35-6. PubMed ID: 8025004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [To improve the survival rate of patients suffering from locally advanced non-small cell lung cancer with combination of radiotherapy and chemotherapy].
    Zhu GY
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):88-90. PubMed ID: 17445466
    [No Abstract]   [Full Text] [Related]  

  • 4. [What is the value of neoadjuvant therapy in bronchial carcinoma?].
    Digel W; Brethner L; Hasse J
    Zentralbl Chir; 2000; 125(4):315-8. PubMed ID: 10829310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-small-cell lung cancer: multimodality approach in stage-III resectable disease.
    Thomas M; Hoffknecht P; Droege C; Baisch A; Reinmuth N; Kreuter M; Lange T; Berdel WE
    Lung Cancer; 2004 Aug; 45 Suppl 2():S99-105. PubMed ID: 15552789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined modality therapy of lung cancer.
    Livingston RB
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2638-47. PubMed ID: 10068267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic management of non-small-cell lung carcinoma (NSCLC) of stage III A].
    Mornex F
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S29-32. PubMed ID: 11924239
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials referral resource. Clinical trials in lung cancer.
    Feigal EG; Cheson BD; Nelson AP
    Oncology (Williston Park); 1997 Nov; 11(11):1686, 1688, 1691, 1694. PubMed ID: 9394366
    [No Abstract]   [Full Text] [Related]  

  • 9. [Is preoperative chemotherapy in locally advanced non-small-cell bronchial carcinoma of value?].
    Betticher DC; von Briel C; Gugger M; Cerny T; Ris HB
    Ther Umsch; 1998 Jul; 55(7):399-401. PubMed ID: 9702102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of non-small-cell lung carcinoma (NSCLC) of stage III B].
    Koukourakis M
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S33-6. PubMed ID: 11924241
    [No Abstract]   [Full Text] [Related]  

  • 11. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodality therapy for stage III non-small-cell lung cancer.
    Farray D; Mirkovic N; Albain KS
    J Clin Oncol; 2005 May; 23(14):3257-69. PubMed ID: 15886313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent issues in the treatment of advanced non-small-cell lung cancer].
    Negoro S
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1671-9. PubMed ID: 9757191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival.
    Steger V; Walles T; Kosan B; Walker T; Kyriss T; Veit S; Dippon J; Friedel G
    Ann Thorac Surg; 2009 Jun; 87(6):1676-83. PubMed ID: 19463576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure patterns of combined modality treatment in lung cancer: the impact of staging.
    Hoekstra CJ; Rijna H; Smit EF; Van Mourik JC; Postmus PE; Lammertsma AA; Hoekstra OS
    Neth J Med; 2002 Mar; 60(1):17-21. PubMed ID: 12074038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resected non-small-cell lung cancer stage I/II: indication for adjuvant/neoadjuvant therapy?
    Hoffmann H
    Lung Cancer; 2004 Aug; 45 Suppl 2():S91-7. PubMed ID: 15552788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined modality therapy for stage III non-small cell lung cancer.
    Stinchcombe TE; Fried D; Morris DE; Socinski MA
    Oncologist; 2006; 11(7):809-23. PubMed ID: 16880240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.
    van Meerbeeck JP; Surmont VF
    Lung Cancer; 2009 Sep; 65(3):257-67. PubMed ID: 19285751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ANITA trial seals the deal for adjuvant therapy in non-small-cell lung cancer.
    Belani CP
    Clin Lung Cancer; 2005 May; 6(6):331-2. PubMed ID: 15943890
    [No Abstract]   [Full Text] [Related]  

  • 20. What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?
    Van Meerbeeck JP; De Pauw R; Tournoy K
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):199-206. PubMed ID: 18279061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.